Homocysteine in cardiovascular disease: A culprit or an innocent bystander?

Indian Journal of Medical Sciences

Volumn 61, Issue 6, 2007, Pages 361-371

  Kothekar, Mudgal ^a,b  

^a Piramal Enterprises Limited   (India)

^b NONE   (India)

Author keywords

Bystander; Cardiovascular; Hyperhomocysteinemia; Risk factor; Therapy

Indexed keywords

CARBAMAZEPINE; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; NICOTINIC ACID; PHENYTOIN; PYRIDOXINE; THEOPHYLLINE; TRIMETHOPRIM;

ACUTE HEART INFARCTION; ACUTE LYMPHOCYTIC LEUKEMIA; ARTERY DISEASE; BIOCHEMISTRY; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; ENZYME DEFICIENCY; FOLIC ACID DEFICIENCY; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHYROIDISM; KIDNEY FAILURE; LIVER DISEASE; METHIONINE SYNTHASE DEFICIENCY; METHYLENE TETRAHYDROFOLATE REDUCTASE DEFICIENCY; OVARY CANCER; PANCREAS CANCER; PUBLIC HEALTH; PYRIDOXINE DEFICIENCY; REVIEW; STROKE; VEIN THROMBOSIS;

EID: 34250173099     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.32687     Document Type: Review

References (27)

1. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
2. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J 2004;3:4.
3. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
4. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
5. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-22.
6. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996;77:759-61.
7. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
8. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
9. Moat SJ, Doshi SN, Lang D, McDowell IF, Lewis MJ, Goodfellow J. Treatment of coronary heart disease with folic acid: Is there a future? Am J Physiol Heart Circ Physiol 2004;287:H1-7.
10. Al-Obaidi MK, Stubbs PJ, Amersey R, Noble MI. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart 2001;85:380-4.
11. 6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: A randomized controlled trial. JAMA 2002;288:973-9.
12. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998;98:2520-6.
13. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002;325:1202-6.
14. Matetzky S, Freimark D, Ben-Ami S, Goldenberg I, Leor J, Doolman R, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med 2003;163:1933-7.
15. Bodi V, Sanchis J, Llacer A, Facila L, Nunez J, Pellicer M, et al. Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. Am Heart J 2005;149:268-74.
16. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual? Arch Intern Med 2000;160:422-34.
17. Bokhari SW, Bokhari ZW, Zell JA, Lee DW, Faxon DP. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. Coronary Artery Dis 2005;16:153-61.
18. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
19. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
20. Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS- Presented at AHA 2006). Presented by Dr. Christine Albert at the American Heart Association Annual Scientific Sessions: Chicago, IL; November 2006, Available from: http://www.medscape.com/viewarticle/548663.
21. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power Shortage: Clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001;135:133-7.
22. rd. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:207-9.
23. Refsum H, Smith AD. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:207.
24. Tomlinson DR, Lang D, Lewis MJ. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:209.
25. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
26. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-6.
27. Wald DS, Wald, NJ, Morris JK, Law M. Folic acid, homocysteine and cardiovascular disease: Judging causality in the face of inconclusive trial evidence. BMJ 2006;333:1114-7.